228 related articles for article (PubMed ID: 35172648)
1. Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches.
Hagiwara Y; Shiroiwa T
Med Decis Making; 2022 Jul; 42(5):672-683. PubMed ID: 35172648
[TBL] [Abstract][Full Text] [Related]
2. A new approach for sample size calculation in cost-effectiveness studies based on value of information.
Bader C; Cossin S; Maillard A; Bénard A
BMC Med Res Methodol; 2018 Oct; 18(1):113. PubMed ID: 30348087
[TBL] [Abstract][Full Text] [Related]
3. Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer.
McCullagh L; Schmitz S; Barry M; Walsh C
Pharmacoeconomics; 2017 Nov; 35(11):1177-1185. PubMed ID: 28770453
[TBL] [Abstract][Full Text] [Related]
4. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.
Eckermann S; Willan AR
Pharmacoeconomics; 2011 Jul; 29(7):563-77. PubMed ID: 21671686
[TBL] [Abstract][Full Text] [Related]
5. Pricing of medical devices under coverage uncertainty--a modelling approach.
Girling AJ; Lilford RJ; Young TP
Health Econ; 2012 Dec; 21(12):1502-7. PubMed ID: 22021085
[TBL] [Abstract][Full Text] [Related]
6. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
7. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
8. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
[TBL] [Abstract][Full Text] [Related]
9. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options.
Mühlbacher AC; Sadler A
Value Health; 2017 Feb; 20(2):266-272. PubMed ID: 28237207
[TBL] [Abstract][Full Text] [Related]
10. [Bayesian approach for the cost-effectiveness evaluation of healthcare technologies].
Berchialla P; Gregori D; Brunello F; Veltri A; Petrinco M; Pagano E
Epidemiol Prev; 2009; 33(3):123-8. PubMed ID: 19776461
[TBL] [Abstract][Full Text] [Related]
11. Value-of-Information Analysis for External Validation of Risk Prediction Models.
Sadatsafavi M; Lee TY; Wynants L; Vickers AJ; Gustafson P
Med Decis Making; 2023 Jul; 43(5):564-575. PubMed ID: 37345680
[TBL] [Abstract][Full Text] [Related]
12. Estimation of Value-Based Price for 48 High-Technology Medical Devices.
Hyeraci G; Trippoli S; Rivano M; Messori A
Cureus; 2023 Jun; 15(6):e39934. PubMed ID: 37287820
[TBL] [Abstract][Full Text] [Related]
13. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
Claxton K; Martin S; Soares M; Rice N; Spackman E; Hinde S; Devlin N; Smith PC; Sculpher M
Health Technol Assess; 2015 Feb; 19(14):1-503, v-vi. PubMed ID: 25692211
[TBL] [Abstract][Full Text] [Related]
14. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.
Fenwick E; Marshall DA; Levy AR; Nichol G
BMC Health Serv Res; 2006 Apr; 6():52. PubMed ID: 16623946
[TBL] [Abstract][Full Text] [Related]
15. Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis.
Goldhaber-Fiebert JD; Cipriano LE
Med Decis Making; 2023; 43(7-8):914-929. PubMed ID: 37698120
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Decision Makers' Constraints on the Outcome of Value of Information Analysis.
Koffijberg H; Knies S; Janssen MP
Value Health; 2018 Feb; 21(2):203-209. PubMed ID: 29477402
[TBL] [Abstract][Full Text] [Related]
17. Bayesian methods in health technology assessment: a review.
Spiegelhalter DJ; Myles JP; Jones DR; Abrams KR
Health Technol Assess; 2000; 4(38):1-130. PubMed ID: 11134920
[TBL] [Abstract][Full Text] [Related]
18. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
19. Uncertainty and the Value of Information in Risk Prediction Modeling.
Sadatsafavi M; Yoon Lee T; Gustafson P
Med Decis Making; 2022 Jul; 42(5):661-671. PubMed ID: 35209762
[TBL] [Abstract][Full Text] [Related]
20. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
